Avatrombopag launch date
Avatrombopag is the world's first FDA approved for CLD An oral thrombopoietin receptor agonist (TPO-RA) associated with thrombocytopenia, avatrombopag is also used to treat thrombocytopenia in patients with chronic immune thrombocytopenia (ITP).

Avatrombopag was approved for marketing in the United StatesFDA in20185 an>2020year8month28The Nikkei China Food and Drug Administration approved the listing, and has been included in medical insurance and belongs to the national Class B medical insurance catalog. The domestic pharmacy price is 20mg10tablets2700yuan, and the retail price of 20mg28tablets600yuan at Lucius Pharmaceutical Factory in Laos is about 600yuan. The retail price of Laos United Pharmaceutical Factory is around 700 yuan for 20 mg of 30 tablets. The retail price of Bangladesh Ziska Pharmaceutical Factory is about 20mg 30 tablets1000yuan. The retail price of Bangladesh Yaopin International Pharmaceutical Factory is around 900 yuan for 20 mg 28 tablets. Patients can choose drug versions based on their financial situation.
Avatrombopag is a thrombopoietin (TPO) receptor agonist that has been associated with thrombotic and thromboembolic complications in patients with chronic liver disease or chronic immune thrombocytopenia. In patients with chronic liver disease, thromboembolic events (portal vein thrombosis) occurred in 0.4% (1/274) of patients receiving DOPTELET. In patients with chronic immune thrombocytopenia, receiveThromboembolic events(arterial or venous) occurred in 7% (9/128) of patients treated with DOPTELET. Patients with chronic liver disease or chronic immune thrombocytopenia should not take DOPTELET to restore platelet counts. Monitor platelet count and follow dosing guidelines to achieve target platelet count. Monitor patients receiving DOPTELET for signs and symptoms of thromboembolic events and initiate treatment promptly. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to help you learn more about high-quality overseas drugs.
xa0
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)